Quick Heal Technologies Ltd
Quick Heal Technologies Q1 FY26: Order Book ₹24 Cr
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth. Quick Heal acknowledges current challenges including softer consumer market and deferred enterprise deals impacting near-term revenue and profitability (Page 4).
From Quick Heal Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth.
- The company acknowledges a gestation period for enterprise cybersecurity business but remains confident in its foundational investments and future growth.
- Recent large deal wins, particularly in data privacy with a tier one BFSI client, boost confidence in future sales growth.
- The consumer (B2C) segment is currently facing softness and declining revenue but remains part of the overall revenue mix.
- Management is focused on driving revenue recovery, managing expenses, and leveraging strategic expansions including international markets.
2 more points from Quick Heal Technologies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Quick Heal Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments by Quick Heal Technologies Limited.
- The company remains focused on continued investments in product development, particularly in building features for their data privacy product and enterprise platform.
- Investment emphasis is on innovation and expanding product functionalities, including AI-driven threat detection and data privacy compliance tools.
- The management is currently investing in strengthening the enterprise business and sales organization, which is considered critical for future growth.
2 more points from Quick Heal Technologies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in IT - Software
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Quick Heal Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Quick Heal disclosed an order book of Rs.24 crores as of the recent quarters.
- There is also a deferred revenue of around Rs.16 crores, indicating revenue visibility.
- The company has not provided specific pipeline numbers currently but acknowledged the importance of doing so for investor clarity.
- Management is working on providing more granularity on order book conversion timelines and pipeline insights in upcoming quarters.
- The pipeline is described as "healthy" and "improving" with good visibility.
- Multiple proof of concepts (POCs) and proposals are ongoing, with expectations of closing more deals soon.
2 more points from Quick Heal Technologies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Quick Heal Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹49 Cr, net loss ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Quick Heal Technologies Ltd's management said in earlier quarters
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY24 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
Others in IT - Software this season
- ASM Technologies (Q1 FY26)
Revenue from Operations for Q1FY26: ₹122.9 Cr. Key concall takeaways from ASM Technologies Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Silver Touch Technologies Ltd (Q1 FY26)
Q1 FY26 Revenue from Operations: ₹627.49 million . Key concall takeaways from Silver Touch Technologies Ltd's Q1 FY26 earnings call — and how it ranks against…
- C.E. Info Systems Ltd (Q1 FY26)
Automotive and mobility tech (A&M) segment showed robust growth of 24.4% YoY despite modest broader automotive industry growth, driven by improved adoption of…
- Tanla Platforms (Q1 FY26)
Q1 FY26 saw consecutive revenue growth: 1.6% QoQ and 3.8% YoY to ₹1,041 crores. Key concall takeaways from Tanla Platforms Ltd's Q1 FY26 earnings call — and…
Arthneeti Pro · Annual
Quick Heal Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Quick Heal Technologies Ltd Q1 FY26 results?
The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth. Quick Heal acknowledges current challenges including softer consumer market and deferred enterprise deals impacting near-term revenue and profitability (Page 4).
What is Quick Heal Technologies Ltd share price analysis?
Quick Heal Technologies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Quick Heal Technologies Ltd planning capital expenditure?
The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments by Quick Heal Technologies Limited.
Keep Quick Heal Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.